News

Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the

These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions.

The pharma giant's latest big

Are you looking for new growth stocks for your portfolio? The idea was compelling a week ago when the market was roaring higher. Now, with fresh headwinds blowing, not so much.

Just bear in mind

Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster

Many investors have flocked to big pharma stocks throughout the years. And doing so has paid off handsomely with several of those stocks.

AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stand out as

In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored

In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored

In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored

My favorite stocks to invest in are those that continuously increase their dividend. Merck & Co (NYSE: MRK) is one stock that I like a lot that has been growing its dividend at a solid clip for a

Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the

Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the

Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the

Stocks have rallied this year, but one of the world's most famous pharma companies didn't join the party. Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine

Stocks have rallied this year, but one of the world's most famous pharma companies didn't join the party. Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine

As the year comes to an end, it's time to think about which stocks to sell for tax-loss harvesting. One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). The company's shares have

As the year comes to an end, it's time to think about which stocks to sell for tax-loss harvesting. One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). The company's shares have

Over long periods, dividend stocks tend to outperform their non-dividend-paying counterparts. There are likely several reasons for this, one of which is that sustaining a dividend program requires a

Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and

Shares of Pfizer (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's

Shares of Pfizer (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's